These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 25594497)

  • 21. Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK.
    Kong X; Sun H; Pan P; Zhu F; Chang S; Xu L; Li Y; Hou T
    Phys Chem Chem Phys; 2018 Feb; 20(7):4851-4863. PubMed ID: 29383359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
    Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
    PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of novel oxazolo[5,4-d]pyrimidines as potent VEGFR-2 inhibitors.
    Deng YH; Xu D; Su YX; Cheng YJ; Yang YL; Wang XY; Zhang J; You QD; Sun LP
    Chem Biodivers; 2015 Apr; 12(4):528-37. PubMed ID: 25879498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of indirubin analogues as phosphorylase kinase inhibitors.
    Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM
    J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles.
    Abdel-Mohsen HT; Abdullaziz MA; Kerdawy AME; Ragab FAF; Flanagan KJ; Mahmoud AEE; Ali MM; Diwani HIE; Senge MO
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32053964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of hydrophobic and hydrogen bonding interactions on the potency of ß-alanine analogs of G-protein coupled glucagon receptor inhibitors.
    Venugopal PP; Das BK; Soorya E; Chakraborty D
    Proteins; 2020 Feb; 88(2):327-344. PubMed ID: 31443129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein-ligand interaction-guided discovery of novel VEGFR-2 inhibitors.
    Zhang Y; Zhang M; Wang Y; Fan Y; Chen X; Yang Y; Hua Y; Xie W; Lu T; Tang W; Chen Y; Liu H
    J Biomol Struct Dyn; 2020 Jun; 38(9):2559-2574. PubMed ID: 31232191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective flexibility of side-chain residues improves VEGFR-2 docking score using AutoDock Vina.
    Abreu RM; Froufe HJ; Queiroz MJ; Ferreira IC
    Chem Biol Drug Des; 2012 Apr; 79(4):530-4. PubMed ID: 22188672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design.
    Shen M; Zhou S; Li Y; Li D; Hou T
    Mol Biosyst; 2013 Oct; 9(10):2435-46. PubMed ID: 23881296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. De novo design of VEGFR-2 tyrosine kinase inhibitors based on a linked-fragment approach.
    Liu YZ; Wang XL; Wang XY; Yu RL; Liu DQ; Kang CM
    J Mol Model; 2016 Sep; 22(9):222. PubMed ID: 27558799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Binding mechanism of CDK5 with roscovitine derivatives based on molecular dynamics simulations and MM/PBSA methods.
    Dong K; Wang X; Yang X; Zhu X
    J Mol Graph Model; 2016 Jul; 68():57-67. PubMed ID: 27371933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights into mechanism of pyrido[2,3-d]pyrimidines as DYRK1A inhibitors based on molecular dynamic simulations.
    Li JJ; Tian YL; Zhai HL; Lv M; Zhang XY
    Proteins; 2016 Aug; 84(8):1108-23. PubMed ID: 27119584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
    Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
    J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
    Konidala KK; Bommu UD; Pabbaraju N
    J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding microscopic binding of macrophage migration inhibitory factor with phenolic hydrazones by molecular docking, molecular dynamics simulations and free energy calculations.
    Xu L; Li Y; Li L; Zhou S; Hou T
    Mol Biosyst; 2012 Sep; 8(9):2260-73. PubMed ID: 22739754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring the interaction between human focal adhesion kinase and inhibitors: a molecular dynamic simulation and free energy calculations.
    Zhan JY; Zhang JL; Wang Y; Li Y; Zhang HX; Zheng QC
    J Biomol Struct Dyn; 2016 Nov; 34(11):2351-66. PubMed ID: 26549408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probing the interaction mechanism of small molecule inhibitors with matriptase based on molecular dynamics simulation and free energy calculations.
    Sun DR; Zheng QC; Zhang HX
    J Biomol Struct Dyn; 2017 Mar; 35(4):755-764. PubMed ID: 26942570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
    Bhojwani HR; Joshi UJ
    Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
    Aziz MA; Serya RA; Lasheen DS; Abdel-Aziz AK; Esmat A; Mansour AM; Singab AN; Abouzid KA
    Sci Rep; 2016 Apr; 6():24460. PubMed ID: 27080011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2D-QSAR study, molecular docking, and molecular dynamics simulation studies of interaction mechanism between inhibitors and transforming growth factor-beta receptor I (ALK5).
    Jiang MN; Zhou XP; Sun DR; Gao H; Zheng QC; Zhang HX; Liang D
    J Biomol Struct Dyn; 2018 Nov; 36(14):3705-3717. PubMed ID: 29064324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.